Buscar

Mostrando ítems 1-9 de 9

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

2019- White, H. D.; Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; [et al.]

Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy

2019- RUIZ BAÑOBRE, JUAN; Areses Manrique, María Carmen; Mosquera-Martinez, J.; Cortegoso Mosquera, Alexandra Sabela; Afonso-Afonso, F. J.; [et al.]

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

2019- Steg, P. G.; Szarek, M.; Bhatt, D. L.; Bittner, V. A.; Bregeault, M. F.; [et al.]

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

2019- Roe, M. T.; Li, Q. H.; Bhatt, D. L.; Bittner, V. A.; Diaz, R.; [et al.]

Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; Covela Rúa, Marta; De La Cámara Gómez, Juan Cruz; González Villaroel, Paula; [et al.]

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen

2019- Martinez Lago, Nieves Purificacion; Carmona Campos, Marta; Gonzalez Villarroel, P; Salgado Fernández, Mercedes; De La Cámara Gómez, Juan Cruz; [et al.]

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

2019- Fernández Montes, Ana; Martinez Lago, Nieves Purificacion; De La Cámara Gómez, Juan Cruz; Covela Rúa, Marta; Cousillas Castiñeiras, A; [et al.]

EPI.14-15 Real World Clinical Experience of the Galician Lung Cancer Group: Afatinib in Patients with EGFR Positive Mutation

2019- AGRASO BUSTO, SARA; VARELA POSE, VANESA; Fernández Nuñez, Natalia; Firvida Perez, Jose Luis; Santome, L.; [et al.]

Comparison of the cost of illness during symptomatic treatment and specific immunotherapy, in patients with allergic asthma to mites: The itaca study

2019- A.I., Tabar; J., Meseguer-Arce; I., Sanchez-Guerrero; Martín Lázaro, Joaquin; M.J., Torres-Jaen; [et al.]